

**Meeting of the expanded
Bangladesh, Bhutan,
India, Nepal and
Sri Lanka (BBINS)
Malaria Drug Resistance
Monitoring Network
(including Indonesia,
Maldives and
Timor-Leste)**

19–21 August 2020



REGIONAL OFFICE FOR

**World Health
Organization**
South-East Asia

Meeting of the Expanded Bangladesh, Bhutan, India, Nepal and Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network (including Indonesia, Maldives and Timor-Leste)

19–21 August 2020

Meeting of the Expanded Bangladesh, Bhutan, India, Nepal and Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network (including Indonesia, Maldives and Timor-Leste)

SEA-MAL-284

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Meeting of the Expanded Bangladesh, Bhutan, India, Nepal and Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network (including Indonesia, Maldives and Timor-Leste), Regional Office for South-East Asia; 2018. License: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

	<i>Page</i>
Abbreviations.....	v
Summary.....	vii
1. Background.....	1
2. Proceedings.....	1
3. Session 1: Updates.....	2
4. Session 2. Country presentations on recent therapeutic efficacy studies/antimalarial drug efficacy surveillance.....	4
4.1 Bangladesh: Dr Afsana Alamgir Khan, Deputy Programme Manager, National Malaria Elimination & ATD Control Programme, Government of the People’s Republic of Bangladesh	4
4.2 India: Dr Neeraj Dhingra, Director, National Vector Borne Disease Control Programme, Government of India	5
4.3 Indonesia: Dr Pranti Sri Mulyani, Staff, National Malaria Control Programme, Republic of Indonesia and Professor Dr Din Syafruddin, Principal Investigator, Eijkman Institute, Jakarta.....	5
5. Session 3. Updates on antimalarial resistance studies, iDES and molecular markers	6
5.1 Different drug efficacy surveillance systems: routine TES, integrated drug efficacy surveillance (iDES) in the context of elimination, and importation: Ms Charlotte Rasmussen, Technical Officer, Global Malaria Programme, WHO/HQ.....	6
5.2 Updates on Kelch 13, P14 and other molecular markers for resistance: Dr Benoit Wikowsky, Head of Unit, Malaria Molecular Epidemiology Unit, Pasteur Institute of Cambodia.....	7
6. Session 4: Integrated drug efficacy surveillance (iDES) in near-elimination/ elimination countries.....	7
6.1 Bhutan: Mr Singye Dukpa, Senior Laboratory Technician, Vector Disease Control Programme, Gelephu	7
6.2 Maldives: Ms Aishath Jaleela, Director, Pharmaceuticals, Food and Drug Authority, Ministry of Health.....	8
6.3 Nepal: Dr Basudev Pandey, Director, Epidemiology and Disease Control Division, Directorate of Health Services, Ministry of Health and Population .	8
6.4 Sri Lanka: Dr Muzrif Munas, CCP, Anti-Malaria Campaign, Ministry of Health Care and Nutrition.....	9
6.5 Timor-Leste: Ms Maria do Rosario de Fatima Mota, Programme Manager, National Malaria Programme, Ministry of Health	10

7.	Session 5: Panel discussion led by Dr Kamini Mendis, Independent Consultant, Sri Lanka, and Dr Pedro Alonso, Director, Global Malaria Programme, WHO-HQ	11
8.	Session 6: Presentation of country plans	11
9.	Session 7: Conclusions and recommendations.....	12
	9.1 Recommendations for the countries.....	12
	9.2 Recommendations for WHO	13

Annexes

1.	Agenda.....	14
2.	List of participants	15

Abbreviations

ACD	active case detection
ACPR	adequate clinical and parasitological response
ACT	artemisinin-based combination therapy
AS	artesunate
BBINS	Bangladesh, Bhutan, India, Nepal, Sri Lanka
CDS	Communicable Diseases Department (of the WHO Regional Office)
CQ	chloroquine
DHA	dihydroartemisinin
ECAMM	External Competency Assessment for Malaria Microscopy
ETF	early treatment failure
GMP	Global Malaria Programme
GMS	Greater Mekong Subregion
GTS	Global Technical Strategy
iDES	integrated drug efficacy surveillance
K13	Kelch 13
LCF	late clinical failure
LPF	late parasitological failure
MQ	mefloquine
NMCP	National Malaria Control Programme
NSP	National Strategic Plan
NTG	National Treatment Guidelines
PCD	passive case detection
PIP	piperaquine
PQ	primaquine
QA	quality assurance
RDT	rapid diagnostic test
SEARO	(WHO) Regional Office for South-East Asia
SP	sulfadoxine-pyrimethamine
TES	therapeutic efficacy studies
WHO	World Health Organization

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?>